ESBR Labs is a research and manufacturing organization, which supports R&D programs from lead generation to clinical studies. We also provide support for Fine chemicals, APIs and API Intermediates, custom synthesis, reference standards, impurity synthesis, small library synthesis and process development & committed to deliver on time. We are strongly committed on client satisfaction, quality, safety, ethics and integrity. Our ability to deliver significant value to our customers by leveraging our scientific skills, global mind set and cost competitiveness differentiates us as one of the most trusted partners.
- Quality and responsibility to all who use our products or services is a fundamental part of our corporate strategy.
- Focus on products with off-patent active pharmaceutical ingredients in the health care and pharmaceutical market. Comprehensive portfolio of generics including selected biosimilars.
- Strategic further development with numerous initiatives introduced to improve performance. Fundamental change to reporting structures carried out – management by operating segments. Selected value-enhancing acquisitions to strengthen the Branded Products and Generics segments.
- In order to grow further, ESBR Labs is relying on both organic growth and value-adding acquisitions. Generics will remain part of ESBR’s core business, and within it growth potentials particularly exist in the expansion in markets with relatively low penetration rates and in the supplementation of the existing portfolio with selected biosimilars.
- In the Generics markets, in which the Group is already active with subsidiaries, ESBR aims to maintain or take leading positions. With the help of continuous growth in the Generics segment, the Group intends to generate financial means, to further expand the often more attractive-margin Branded Products area and gradually increase the share of this segment in Group sales as a result.
- Within Branded Products, ESBR is aiming for both further expansion and the increasing internationalization of successful brands. Innovative marketing concepts are to be used in this context. Alongside the strengthening of the Generics and Branded Products segments, ESBR intends to take advantage of additional growth opportunities in niche and non-regulated markets through the introduction of innovative products.
- Sustainable and responsible economic activity is firmly anchored in our company’s history. Our generics portfolio contributes to efficient and affordable healthcare for society. Branded products help to ease the strain on healthcare systems. With innovative business segments, we are a part of medical progress. ESBR makes the most significant contribution for sustainable social development in its core business.
- Our safe products, good Corporate Governance, the conservation of resources, knowledgeable healthcare information and a comprehensive employee program provide long-term security for our strong market position.